Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Biological Standardization of Blomia Tropicalis Allergen Extract

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Kiungo kimehifadhiwa kwenye clipboard
HaliImekamilika
Wadhamini
Laboratorios Leti, S.L.

Maneno muhimu

Kikemikali

The objective of this study is to determine the biologic activity of a Blomia tropicalis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

Maelezo

This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.

Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.

Tarehe

Imethibitishwa Mwisho: 04/30/2012
Iliyowasilishwa Kwanza: 05/09/2012
Uandikishaji uliokadiriwa Uliwasilishwa: 05/09/2012
Iliyotumwa Kwanza: 05/13/2012
Sasisho la Mwisho Liliwasilishwa: 11/28/2012
Sasisho la Mwisho Lilichapishwa: 11/29/2012
Tarehe halisi ya kuanza kwa masomo: 03/31/2012
Tarehe ya Kukamilisha Msingi iliyokadiriwa: 08/31/2012
Tarehe ya Kukamilisha Utafiti: 08/31/2012

Hali au ugonjwa

Allergy to Mites

Uingiliaji / matibabu

Biological: 1

Awamu

Awamu 2

Vikundi vya Arm

MkonoUingiliaji / matibabu
Experimental: 1
Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml) Positive control Negative control
Biological: 1
Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.

Vigezo vya Kustahiki

Zama zinazostahiki Kujifunza 18 Years Kwa 18 Years
Jinsia Inastahiki KujifunzaAll
Hupokea Wajitolea wa AfyaNdio
Vigezo

Inclusion Criteria:

1. A documented positive case history with inhalation allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) related to Blomia tropicalis.

2. Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).

3. Subject can be male or female of any race and ethnic group.

4. Age > 18 years and < 50 years at the study inclusion day.

5. Positive skin prick test with a standardized commercially available preparation of Blomia tropicalis allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm and at least the size of the positive control. Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study

6. A positive test for specific IgE to Blomia tropicalis(CAP-RAST ≥ 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.

7. Allergic symptoms during the season of Blomia tropicalis.

8. Mean of the forearm major diameters of the wheals provoked by histamine dihydrochloride (10 mg/ml) ≥ 3 mm.

Exclusion Criteria:

1. Immunotherapy in the past 5 years with an allergen preparation known to interfere with the allergen to be tested (e.g., mites group extracts).

2. Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1

3. Treatment with any of the following medications: tricyclic or tetracyclic antidepressants, β-blockers or corticosteroids (> 10 mg/day of prednisone or equivalent).

4. Pregnancy.

5. Dermographism affecting the skin area at the test site at either study visit.

6. Atopic dermatitis affecting the skin area at the test site at either study visit.

7. Urticaria affecting the skin area at the test site at either study visit.

8. Participation in another clinical trial within the last month.

9. Subjects suffering from pathologies or conditions in which adrenalin is contraindicated (heart disease, severe hypertension,...)

Matokeo

Hatua za Matokeo ya Msingi

1. Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase. [Test sites should be inspected and recorded 15-20 min after application]

Jiunge na ukurasa
wetu wa facebook

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

  • Inafanya kazi katika lugha 55
  • Uponyaji wa mitishamba unaungwa mkono na sayansi
  • Kutambua mimea kwa picha
  • Ramani ya GPS inayoshirikiana
  • Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
  • Tafuta mimea ya dawa na athari zao
  • Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa

Google Play badgeApp Store badge